Lifeboat Foundation

In a new study, Deepmind and colleagues at Isomorphic Labs show early results from a new version of AlphaFold that brings fully automated structure prediction of biological molecules closer to reality.

The Google Deepmind AlphaFold and Isomorphic Labs team today unveiled the latest AlphaFold model. According to the companies, the updated model can now predict the structure of almost any molecule in the Protein Data Bank (PDB), often with atomic accuracy. This development, they say, is an important step towards a better understanding of the complex biological mechanisms within cells.

Since its launch in 2020, AlphaFold has influenced protein structure prediction worldwide. The latest version of the model goes beyond proteins to include a wide range of biologically relevant molecules such as ligands, nucleic acids and post-translational modifications. These structures are critical to understanding biological mechanisms in cells and have been difficult to predict with high accuracy, according to Deepmind.

Nanotechnology sounds like a futuristic development, but we already have it in the form of CPU manufacturing. More advanced nanotech could be used to create independent mobile entities like nanobots. One of the main challenges is selecting the right chemicals, elements, and structures that actually perform a desired task. Currently, we create more chemically oriented than computationally oriented nanobots, but we still have to deal with the quantum effects at tiny scale.

One of the most important applications of nanotechnology is to create nanomedicine, where the technology interacts with biology to help resolve problems. Of course, the nanobots have to be compatible with the body (e.g. no poisonous elements if they were broken down, etc).

Continue reading “How nanobots and nanomedicine will improve our health” »

This Review discusses how embryonic transcriptional programs, such as epithelial–mesenchymal plasticity and stemness, may be harnessed in adult tissues to drive processes and diseases such as regeneration and cancer.

https://youtube.com/watch?v=ZzsM2wd9h8k

C60 Evo delivers an incredible study that shows eradication of tumors & 90% increase In life with C60 Evo co-owners Patty Greer & Chris Burns and RedPill 78. We discuss the difference between industrial grade Carbon 60 and our Pure C60 “ESS60” made specifically for humans and pets. Three incredible organic edible oils, two different facial serum’s, hair, renewal products, and even lip balm’s infused with pure C60 ESS60 for maximum benefits. We sell all over the world, and people +are pets are healing daily! C60Evo.com

Nano electron guns can help zap cancers and drive new classes of lasers.

From medication to therapy, see how you can relieve back pain caused by ankylosing spondylitis of the spine.

A cholesterol-lowering drug may help reduce the risk of heart failure in people with lymphoma who receive chemotherapy drugs called anthracyclines, results from a clinical trial suggest.

Anthracyclines, such as doxorubicin, are used to treat many types of cancer. But these drugs may affect the heart’s ability to pump blood, potentially leading to heart failure.

In the trial, atorvastatin (Lipitor) was found to reduce the risk of some cardiac changes linked to heart failure among patients treated with anthracyclines.

The anti–PD-1 agent tislelizumab was noninferior, but not superior, to the tyrosine kinase inhibitor sorafenib for unresectable hepatocellular cancer.

First-line treatment for patients with unresectable hepatocellular cancer (HCC) is either combination immunotherapy with bevacizumab and atezolizumab or tremelimumab and durvalumab. Although immunotherapy-based combination therapy has replaced tyrosine kinase inhibitors (TKIs) as initial therapy, randomized trials have not indicated superiority of single agent anti–PD-1 or PD-L1 therapy over TKIs.

Investigators have now conducted an industry-sponsored, global, open-label, randomized, phase 3 trial (RATIONALE-301) to compare first-line treatment with the anti–PD-1 agent tislelizumab versus the TKI sorafenib in 674 patients with Child-Pugh class A unresectable HCC. Of the patients, 85% were men, 58% had distant metastases, 76% had received prior locoregional therapy, 60% had hepatitis B, 13% had hepatitis C, and 3% had hepatitis B and C.

The primary endpoint of noninferiority for overall survival (OS) was achieved with tislelizumab compared with sorafenib (median 15.9 vs. 14.1 months; hazard ratio, 0.85; 95% confidence interval, 0.71–1.02), reaching the noninferiority margin upper limit of a hazard ratio 1.08. Superiority for OS with tislelizumab was not met. Antitumor response was numerically higher with tislelizumab than with sorafenib (14.3% vs. 5.4%), and median duration of response was longer with tislelizumab than with sorafenib (36.1 vs. 11.0 months). Median progression-free survival was similar with tislelizumab and sorafenib (2.1 and 3.4 months, respectively). Grade 3–4 treatment-related adverse events were more common with sorafenib than with tislelizumab (53.4% vs. 22.2%).

Continue reading “Tislelizumab vs. Sorafenib for Unresectable Hepatocellular Cancer” »

An international research consortium led by Ludwig Maximilian University of Munich (LMU) has tested a rapid new analytical tool which needs just a blood sample from the fingertip.

About 240,000 children worldwide die of tuberculosis every year. The disease is among the top 10 causes of death in children under the age of 5. One of the main reasons for this mortality is that tuberculosis is often misdiagnosed or not diagnosed in time, particularly in regions with limited resources.

A new diagnostic tool, which an international research consortium led by LMU medical scientists Laura Olbrich and Norbert Heinrich from the Division of Infectious Diseases and Tropical Medicine at LMU University Hospital Munich has tested as part of a large-scale study in five countries, offers significant progress in this area. The authors report on their findings in The Lancet Infectious Diseases.